Xi et al. developed a novel targeted therapeutic strategy using FLT3L-guided miR-150-based nanoparticles to treat FLT3-overexpressing AML in an animal model with high efficacy and minimal side effects [54]. Here, FLT3LG is linked to acute myeloid leukemia.